KCS Wealth Advisory bought a new position in Humana Inc (NYSE:HUM) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm bought 1,073 shares of the insurance provider’s stock, valued at approximately $266,000.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Koch Industries Inc. acquired a new stake in shares of Humana during the 2nd quarter worth approximately $404,000. Adviser Investments LLC acquired a new stake in shares of Humana during the 3rd quarter worth approximately $635,000. Wells Fargo & Company MN increased its holdings in shares of Humana by 10.0% during the 3rd quarter. Wells Fargo & Company MN now owns 1,653,318 shares of the insurance provider’s stock worth $402,799,000 after buying an additional 150,173 shares during the last quarter. Commonwealth Bank of Australia increased its holdings in shares of Humana by 3.9% during the 3rd quarter. Commonwealth Bank of Australia now owns 21,112 shares of the insurance provider’s stock worth $5,138,000 after buying an additional 796 shares during the last quarter. Finally, Icon Advisers Inc. Co. increased its holdings in shares of Humana by 22.7% during the 3rd quarter. Icon Advisers Inc. Co. now owns 5,400 shares of the insurance provider’s stock worth $1,316,000 after buying an additional 1,000 shares during the last quarter. 94.01% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have recently issued reports on HUM. Jefferies Group upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $221.00 price target for the company in a report on Friday. Goldman Sachs Group began coverage on shares of Humana in a report on Wednesday, January 3rd. They set a “buy” rating and a $305.00 price target for the company. ValuEngine downgraded shares of Humana from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. Cowen restated a “buy” rating and set a $285.00 price target on shares of Humana in a report on Wednesday, December 13th. Finally, Cantor Fitzgerald restated a “hold” rating and set a $230.00 price target on shares of Humana in a report on Tuesday, December 5th. Ten research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $258.90.
Shares of Humana Inc (NYSE HUM) opened at $268.02 on Friday. Humana Inc has a 1-year low of $186.25 and a 1-year high of $271.99. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.61 and a quick ratio of 1.61. The firm has a market cap of $38,289.34, a P/E ratio of 22.87, a P/E/G ratio of 1.74 and a beta of 0.88.
Humana (NYSE:HUM) last posted its earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.27 by $0.12. Humana had a net margin of 3.49% and a return on equity of 15.99%. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $13.41 billion. During the same quarter last year, the firm earned $3.18 EPS. The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. equities analysts expect that Humana Inc will post 11.63 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be issued a $0.40 dividend. The ex-dividend date is Thursday, December 28th. This represents a $1.60 annualized dividend and a yield of 0.60%. Humana’s dividend payout ratio (DPR) is presently 12.59%.
Humana declared that its board has approved a stock buyback program on Thursday, December 14th that allows the company to repurchase $3.00 billion in shares. This repurchase authorization allows the insurance provider to reacquire shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.
In other Humana news, SVP Jody L. Bilney sold 7,054 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $247.89, for a total value of $1,748,616.06. Following the completion of the transaction, the senior vice president now owns 11,704 shares in the company, valued at $2,901,304.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Brian P. Leclaire sold 1,679 shares of the business’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $245.97, for a total transaction of $412,983.63. Following the completion of the transaction, the senior vice president now owns 9,888 shares of the company’s stock, valued at approximately $2,432,151.36. The disclosure for this sale can be found here. Insiders sold a total of 10,115 shares of company stock valued at $2,501,627 in the last quarter. 0.80% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/14/kcs-wealth-advisory-takes-266000-position-in-humana-inc-hum.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.